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Abstract
Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis characterized by bone erosion mediated by
osteoclasts (OC). Our previous studies showed an elevated frequency of OC precursors (OCP) in PsA patients. Here,
we examined if OC arise from CD16-positive monocytes in PsA.
Methods: Peripheral blood mononuclear cells (PBMC) or monocytes were isolated from human peripheral blood
and sorted based on CD16 expression. Sorted cells were cultured alone or with bone wafers in the presence of
receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF).
Enumeration and bone erosion activity of OC were examined after culture. The effects of tumor necrosis factor-
alpha (TNFa), OC-promoting (M-CSF plus RANKL), and dendritic cell (DC)-promoting (GM-CSF plus interleukin (IL)-4)
cytokines on CD16 surface expression were examined by flow cytometry.
Results: PsA and psoriasis (Ps) subjects had a higher percentage of circulating inflammatory CD14+CD16+ cells
than healthy controls (HC). Exposure of cells to OC-promoting, but not DC-promoting media, was associated with
CD16 up-regulation. PBMC of Ps and PsA had a higher frequency of cells expressing intermediate levels of CD16.
OC were mainly derived from CD16+ cells in PsA. Increased CD16 expression was associated with a higher bone
erosion activity in PsA.
Conclusions: An increased frequency of circulating CD14+CD16+ cells was noted in PsA compared to controls,
and intermediate levels of CD16 may suggest a transitional state of OCP during osteoclastogenesis. Intriguingly,
TNFa blocked CD16 expression on a subset of CD14+ monocytes. Collectively, our data suggest that CD16 has the
potential to serve as an OCP marker in inflammatory arthritis.
Introduction
Psoriatic arthritis (PsA) is an inflammatory joint disease
characterized by joint destruction in the majority of
patients within two years of disease onset [1]. Joint
damage is carried out by synovial fibroblastoid cells that
degrade cartilage through the release of metalloprotei-
nases and osteoclasts (OC), which directly resorb bone.
OC are multinucleated cells that arise from osteoclast
precursors (OCP) or circulating CD14+ monocytes
through a differentiation process referred to as osteo-
clastogenesis [2]. Of particular interest in regards to PsA
was the finding of an increased frequency of OCP in
one-third of patients with psoriasis (Ps) without arthritis
and in the majority of PsA patients [3]. Intriguingly,
monocytes circulating in the peripheral blood of PsA
patients were able to generate OC in vitro in the
absence of exogenous stimulation [3], a property distinct
from OCP in healthy controls (HC). Importantly, the
frequency of OCP correlated with the extent of radio-
graphic damage in a cohort of patients with established
PsA [3]. Thus, identification of specific surface markers
of OCP is of great interest, given that the current assess-
ment of OCP requires laborious, expensive, and time-
consuming cell culture.
For the current study, we chose CD16, the low-affinity
immunoglobulin (Ig) G Fcg receptor (FcgRIIIa), as a
candidate cell surface marker of OCP for several rea-
sons. First, the CD16+ human monocyte subset is con-
sidered ‘pro-inflammatory’ [4-6]. These cells exhibit
several unique properties with characteristics of an OCP
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population. The CD16+ monocyte subset is rare in
healthy controls [5], but is preferentially expanded two-
to four-fold during infection or inflammation [5-10].
Moreover, the percentage of CD16+ cells (5 to 10%) in
human peripheral blood monocytes falls into a reason-
able range for the OCP population. Second, CD16+ cells
are expanded in the circulation of patients with rheuma-
toid arthritis (RA) and they are present in rheumatoid
synovial tissue [11]. Importantly, this population is also
expanded in the circulation of patients with aseptic joint
loosening and osteolysis [12]. Third, CD14+CD16+ cells
release TNFa and IL-6, cytokines that can greatly
potentiate osteoclastogenesis and activate OCs, respec-
tively [13]. CD16 is an oligomeric complex composed of
one Fc-binding a chain associated with homodimers or
heterdimers of the T-cell receptor ζ (TCR-ζ) and the g
subunit of FcεRI (FcRg) [14], and thus belongs to the
family of the multichain immunorecognition receptors
[15]. The presence of the immunoreceptor tyrosine-
based activation motif (ITAM) in the FcRg subunit of
CD16 complex notably accentuates the role of CD16 in
signaling [16,17].
Previously, we showed that PsA patients have an ele-
vated frequency of circulating OCP in their peripheral
blood [3]. Based on the properties of the CD14+CD16+
population outlined above, we hypothesized that OCP in
PsA arise from the CD16+ monocyte subset and thus,
the CD16 molecule might serve as an OCP marker in
PsA. To this end, we examined the expression of the
CD16 molecule in a cohort of HC, Ps, RA, and PsA
patients. We also examined the relation between CD16




All clinical studies were carried out with the approval of
the University of Rochester Medical Center Research
Subjects Review Board and with informed consent. PsA
was diagnosed according to the Moll and Wright Cri-
teria [18]. Subjects with inflammatory arthritis were
recruited from the faculty clinics at the University of
Rochester Medical Center and Ps subjects from our
Psoriasis Center. HCs had no acute or chronic joint
pain and were in good health. None of the patients or
controls was taking medication.
Cell isolation
Peripheral blood mononuclear cells (PBMC) were sepa-
rated from the whole blood by Ficoll gradient. Briefly,
the blood sample was first diluted twice in sterile PBS
and overlaid onto Ficoll-Paque PLUS (GE Healthcare,
Piscataway, NJ, USA), soft spun at 2250 rpm for 45 min-
utes at room temperature without brake. PBMC were
collected at the plasma/ficoll interface and washed once
with PBS. Erythrocytes were lysed with ACK lysing buf-
fer (BioWhittaker, Walkersville, MD, USA) and the
remaining cells were washed twice with PBS in prepara-
tion for culture.
Monocyte enrichment
Human monocytes were enriched by either positive or
negative selection. Positive selection was performed with
the CD14 MicroBeads (Miltenyi Biotec, Auburn, CA,
USA) that bind to CD14 on the surface of monocytes.
Negative selection was performed with the Human
Monocyte Enrichment Cocktail (StemCell, Vancouver,
Canada) that depletes lymphocytes by rosetting but
leaves monocytes untouched. Both enrichment protocols
were performed following manufacturers’ instructions.
Reagents and antibodies
Antibodies were purchased from BD Bioscience (San
Jose, CA, USA) except the FITC-conjugated anti-MHCII
(DP/DQ/DR) antibody (Ancell, Bayport, MN, USA).
Receptor activator of nuclear factor kappa-B ligand
(RANKL), macrophage colony-stimulating factor
(M-CSF), and TNFa were purchased from R&D systems
(Minneapolis, MN, USA). Defined fetal bovine serum
was obtained from Hyclone (Logan, UT, USA).
OC culture and TRAP staining
Purified PBMC or monocytes were cultured in RPMI
(Gibco/Invitrogen, Grand Island, NY, USA), supplemen-
ted with 8% heat-inactivated fetal bovine serum, 2 mM
glutamine, 50 units/ml penicillin, and 50 ug/ml strepto-
mycin. RANKL (100 ng/ml) and M-CSF (25 ng/ml)
were added to cell culture to stimulate OC generation. 1
× 105 of PBMC or monocytes (1 × 106 cells/ml) were
cultured in one well of 96-well plate with triplicates in
5% carbon dioxide at 37°C. Media were replenished
every two days. On day eight, cells were fixed with 3%
formaldehyde and stained for tartrate-resistant acid
phosphatase (TRAP; Sigma, St. Louis, MO, USA), and
were examined by light microscope. TRAP+ cells with
three or more nuclei were counted as OCs. To examine
the effect of TNFa on CD16 expression, human PBMC
were cultured in either plain media or media supple-
mented with TNFa (25 ng/ml) for three days, followed
by antibody staining and flow cytometry analysis.
Cell sorting and flow cytometry analysis
For sterile cell sorting, PBMC prepared from Ficoll gra-
dient were re-suspended in sterile PBS at 10 × 106 cells/
ml and incubated with anti-human CD16-PE (Clone
3G8, BD Bioscience, San Diego, CA, USA) and anti-
human MHCII-FITC (Clone TDR31.1, Ancell, Bayport,
MN, USA) antibodies for 30 minutes at 4°C. Cells were
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washed twice with PBS, re-suspended in PBS (5 × 106
cells/ml) and subjected to sterile sorting by FACS Van-
tage (Becton Dickinson Immunocytometry Systems,
Bedford, MA, USA). After sorting, 1 × 105 cells were
cultured in one well of a flat 96-well plate in the
presence of RANKL and M-CSF for eight days, and
TRAP-stained for OC enumeration. For flow cytometry
analysis, cells were harvested, washed once with PBS,
and stained with antibody cocktails for 30 minutes at 4°
C. Cells were then washed twice with PBS, fixed, and
analyzed by FACSCalibur, FACScanto, or LSRII with
appropriate compensations. Flow data were analyzed by
CellQuest software version 3.5.1 (Becton Dickinson
Immunocytometry Systems, Bedford, MA, USA) or
Flowjo software (Treestar, Ashland, OR, USA).
Assessment of bone erosion via micro CT
Bone wafers were scanned via high-resolution in vivo
micro-computed tomography (VivaCT40, Scanco,
Southeastern, PA, USA) at an isotropic resolution of
17.5 m with 55 keV cone beam mode. The scanned data
were reconstructed via Scanco software into Dicom files
and further analyzed by the Amira 3.1 software. A den-
sity threshold of more than 11,000 AU was set in the
SurfaceGen module to visualize the bone.
Statistical analysis
One-way analysis of variance with Tukey’s post hoc mul-
tiple comparison test was used to compare four different
groups in Figure 1(b) and Table 1. The two-sample
t-test was used for comparison of two groups with con-
tinuous data. The significance level was set at 0.05. The
Satterthwaite two-sample test was used to analyze data
presented in Figure 1(c). The Fisher’s exact test was
used to analyze the frequencies of CD16 expression pre-
sented in Table 1. All statistical analyses were performed
on SAS 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
The CD14+CD16+ monocyte subset is increased
in PsA patients
Based on CD16 expression and the monocyte classifica-
tion criteria set by Strauss-Ayali and colleagues [5],
human CD14+ monocytes can be divided into two sub-
sets, classical and non-classical, as shown in Figure 1(a).
Several studies have demonstrated that the pro-inflam-
matory, ‘non-classical’ CD14+CD16+ monocyte subset is
expanded in many inflammatory diseases including RA
[7,9,19]. Recently, the expansion of this subset was also
found in patients with aseptic loosening [12]. However,
the frequency of this unique monocyte subset in Ps and
PsA subjects is unknown. To this purpose, we examined
the percentage of CD14+CD16+ monocytes in a cohort
of Ps (n = 29) and PsA (n = 29) subjects and compared
the findings with those in HC (n = 16) and patients
with RA (n = 8). It is important to note that none of
these subjects were on disease modifying anti-rheumatic
drugs (DMARDs) or anti-TNF medications.
As shown in Figure 1(b), the percentage of CD14
+CD16+ cells in Ps, PsA, RA and HC were 0.82 ±
0.60%, 0.91 ± 0.62%, 0.57 ± 0.21%, and 0.46 ± 0.30%,
respectively. The average percentage of CD14+CD16+
cells in Ps and PsA patients increased 1.8- to 2-fold over
levels in HC. A significant difference was observed when
PsA subjects were compared with controls (P = 0.04).
However, it is noteworthy that the percentage of CD14
+CD16+ cells varied considerably between individuals
(shown by distributions of dots in Ps and PsA subjects,
Figure 1(b)). These results are summarized in the
(a) column of Table 1.
Based on the current concept that monocytes are the
major reservoir of human OCP, we further analyzed the
percentage of CD14+CD16+ cells on enriched mono-
cytes (Figure 1(c)). The percentage of purified mono-
cytes that expressed CD14+CD16+ was 2.6 ± 1.6% in
HC (Figure 1(c)-a, n = 11), a number close to the result
published by Ancuta and colleagues [20]. Notably, the
percentage of CD14+CD16+ cells was significantly
increased in PsA patients (Figure 1(c)-b, 10.3 ± 9.5%,
n = 9; P = 0.04). Taken together, results from PBMC
(Figure 1(b)) and enriched monocytes (Figure 1(c))
demonstrate a significant expansion of CD14+CD16+
cells in Ps and PsA patients.
CD16 surface expression is up-regulated by
osteoclastogenic cytokines
It is known that OC and myeloid dendritic cells (DC)
are derived from the same hematopoietic monocytic
progenitor cells [21]. Human monocytes mature into
OC in the presence of RANKL and M-CSF, and differ-
entiate into DC when exposed to IL-4 and granulocyte-
macrophage colony-stimulating factor (GM-CSF) [22].
We postulated that the surface expression of CD16 on
monocytes might be essential for OC development but
not for DC differentiation. To test this hypothesis, we
compared the effect of RANKL + M-CSF with GM-CSF
+ IL-4 on CD16 surface expression.
The cell surface expression of CD16 was monitored at
two different time points after monocytes were purified
from PBMC and cultured in plain, OC-promoting
(RANKL + M-CSF), or DC-promoting (GM-CSF + IL-4)
media (Figure 2(a)). Anti-CD16-PE, anti-CD14-allophy-
cocyanin (APC) antibodies and 7-amino-actinomycin D
(AAD) were included in our antibody staining panel.
PBMC was first gated using forward scatter/side scatter
(FSC/SSC) followed by dead cell exclusion by 7-AAD.
Freshly isolated human monocytes are heterogeneous in
regard to CD16 surface expression, and the majority of
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Figure 1 Ps and PsA patients have a higher percentage of CD14+CD16+ cells. Human peripheral blood mononuclear cells (PBMC) were
isolated from peripheral blood, stained with an antibody cocktail composed of CD14-APC, CD16-PE, 7AAD, and analyzed by flow cytometry.
Dead cells were excluded by 7AAD+. (a) Classical (CD14+CD16-, red line) and non-classical (CD14+CD16+, blue line) monocytes were labeled
based on the classification by Strauss-Ayali and colleagues [5]. (b) The percentage of CD14+CD16+ cells in the PBMC of 16 healthy controls (HC),
and 29 psoriasis (Ps), 28 psoriatic arthritis (PsA), and 8 rheumatoid arthritis (RA) patients. (c) The percentage of CD14+CD16+ cells in enriched
human monocytes from HC and PsA. Monocytes were enriched by the Human Monocyte Enrichment Cocktail. The percentage of CD14+CD16+
cells in enriched monocytes from HC (2.6 ± 1.6%) and PsA patients (10.3 ± 9.5%) are shown in [a] and [b], respectively. The data are
representative of 10 independent experiments.
Table 1 Percentage of CD14+CD16+ cells in total PBMC and CD16int cells in Ps, PsA, RA and HC populations
(a) (b) (c)
Number of subjectsb % of subjectc
% of CD14+CD16+ in total PBMCa with CD16int without CD16int with CD16int
Ps (n = 29) 0.82 ± 0.60 25 4 86
PsA (n = 29) 0.91 ± 0.62 19 9 67
RA (n = 8) 0.57 ± 0.21 5 3 61
HC (n = 16) 0.46 ± 0.30 8 11 42
a Total PBMC were purified by Ficoll gradient, stained with PE-CD16, allophycocyanin (APC)-CD14 antibodies and analyzed by flow cytometry. Dead cells were
excluded by 7-amino-actinomycin D (AAD).
b Number of subjects with or without CD16int. CD16int cells.c Percentage of subjects with CD16int.
HC = healthy control; PBMC = peripheral blood mononuclear cells; Ps = psoriasis; PsA = psoriatic arthritis; RA = rheumatoid arthritis.
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cells are CD16- (blue line in Figure 2(a)-a). After 24
hours in culture, the expression of CD16 increased in all
culture conditions (Figure 2(a)-b). A significant polariza-
tion of CD16 cell surface expression was observed when
cells were cultured for a longer period of time. By day
three (Figure 2(a)-c), CD16 surface expression decreased
on cells cultured in IL4+GM-CSF (green line in Figure
2(a)-c), but increased on cells cultured in RANKL+M-
CSF (pink line in Figure 2(a)-c). Our results showed
that CD16 upregulation occurred when monocytes were
driven into OC but not DC lineage.
Next, we examined the dynamic expression of CD16
in relation to CD14 during OC differentiation. The
expression of CD16 and CD14 was monitored after
PBMC were cultured in OC-promoting media (RANKL
+M-CSF) on day 0, day 3, and day 5, respectively
(Figures 2(b), a to 2c). Intriguingly, CD14+ monocytes
showed a gradual increase of CD16 expression (shown
by arrows in Figures 2(b), a-c). We identified a
population that expressed an intermediate level of CD16
(arrow in Figure 2(b)-b) during the conversion of CD16-
(arrow in Figure 2(b)-a) toward CD16+ (arrow in Figure
2(b)-c). These data indicated that OCPs may undergo a
transitional differentiation stage (shown by arrow in
Figure 2(b)-b) before they develop into mature OC and
upregulate CD16 to a maximal level (Figure 2(b)-c).
A subset of PBMC expresses intermediate levels of CD16
Based on the intermediate level of CD16 expression dur-
ing osteoclastogenesis in vitro (Figure 2(b)-b), we
assumed that a similar transition in CD16 expression
might also occur in vivo. To explore this possibility, we
examined CD16 expression on the same cohort of
enrolled subjects referred to Figure 1(b) data (HC, n =
16; RA, n = 8; Ps, n = 29; PsA, n = 29). Intriguingly, we
observed that PBMC of some subjects had a population
with intermediate CD16 surface expression (Figures 3
(a), b-d). Cells with intermediate expression of CD16
Figure 2 Cytokines alter the cell surface expression of CD16 and human CD14+ cells undergo a transitional stage of CD16 up-
regulation in OC-promoting culture conditions. (a) Enriched human monocytes were cultured in osteoclast (OC)-promoting media (receptor
activator of nuclear factor kappa-B ligand (RANKL) + macrophage colony-stimulating factor (M-CSF), pink line) or dendritic cell (DC)-promoting
media (IL-4 + granulocyte-macrophage colony-stimulating factor (GM-CSF), green line). Freshly isolated monocytes (blue line) and the isotype
control (black line) are also shown. Surface expression of CD16 was monitored by FACS analysis on [a] day 0, [b] day 1, and [c] day 3,
respectively. (b) Human peripheral blood mononuclear cells (PBMC) were cultured in OC-promoting media (RANKL + M-CSF) and the cell surface
expression of CD14 and CD16 was monitored on [a] day 0, [b] day 3, and [c] day 5. Data shown here are live cells after forward scatter/side
scatter (FSC/SSC) gating followed by dead cell exclusion using 7-amino-actinomycin D (AAD). Numbers shown in each quadrant are the
percentage of total gated cells.
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were designated as CD16int. Some subjects had only
CD16+ and CD16- populations without CD16int (Figure
3(a)-a). Although CD16int cells were found in HC and
patients, the frequency of individuals with CD16int cells
was significantly higher in patients than HC (86%, 67%,
61%, and 42% for Ps, PsA, RA, and HC, respectively; P
= 0.01; columns b and c in Table 1). We further exam-
ined the expression of CD16int cells in relation to CD14.
Interestingly, CD16int cells could be CD14- (arrow in
Figure 3(b)-b) or CD14+ (arrow in Figure 3(b)-c). Col-
lectively, our data provide direct evidence that up-regu-
lation of CD16 does occur in vivo in human peripheral
blood (Figures 3(a) and 3(b)), similar to the findings
observed in vitro (Figure 2(b)). Therefore, it is conceiva-
ble that CD16int cells represent a cell population under-
going a transitional state toward OC differentiation.
CD16+ cells are the major reservoir of OCP
in PsA patients
To determine if CD16+ cells are the reservoir for OCP,
we sterile sorted CD16+ and CD16- cells and compared
their osteoclastogenic potential. Due to a low absolute
number of CD14+CD16+ cells in total PBMC (Figure 1
(b) and column (a) in Table 1, range from 0.46 to 0.91%),
we were unable to obtain enough sorted cells for OC cul-
ture in vitro. Because osteoclastogenesis is cell concentra-
tion dependent [23], cells cultured below a critical
threshold density fail to encounter their fusion partners
and thus cannot form multinucleated OC. To overcome
the technical difficulty in obtaining enough cells for OC
culture, we took two approaches. First, we obtained a
large quantity of blood (about 400 ml) from hemochro-
matosis subjects undergoing therapeutic phlebotomy and
sterile sorted CD14+CD16+ cells. Blood collected from
hemochromatosis subjects was considered as controls in
our study, because they were otherwise healthy without
comorbid disorders. We were able to obtain enough
CD14+CD16+ and CD14+CD16- cells for OC culture
from these subjects after sterile sorting. The numbers of
OC derived from 105 of the sorted CD14+CD16+ and
CD14+CD16- cells were 40 ± 6 and 420 ± 38, respec-
tively. This result is in accordance with the previous find-
ings by Komano and colleagues [24] in which OC were
derived from the CD16- subset in healthy individuals.
Second, we chose to sort MHCII+CD16+ instead of
CD14+CD16+ in order to obtain enough cells for OC
Figure 3 Cells that express intermediate levels of CD16 (CD16int) are found in vivo in human PBMC. (a) CD16 expression on human
peripheral blood mononuclear cells (PBMC) is heterogeneous. The data shown here are the representatives of CD16 expression patterns on fresh
human PBMC from 82 subjects. [a] PBMC that expressed high and low levels of CD16 without the CD16int population. [b to d] PBMC that have
CD16int populations with different CD16 expression levels. (b) Ex vivo analysis of CD14 and CD16 expression. Representative examples of
individuals [a] without a CD16int population, [b] CD14- CD16int (arrow) cells and [c] CD14+ CD16int (arrow) cells are shown. In total, 16 healthy
control (HC), 29 psoriasis (Ps), 29 psoriatic arthritis (PsA), and 8 rheumatoid arthritis (RA)patients were included in this analysis. See Table 1 for the
summary of CD16int percentage in HC, Ps, PsA and RA groups.
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culture. CD14+CD16+ cells are a subset (30 to 50%) of
MHCII+CD16+ cells (Figure 4(a)-e). This conclusion was
reached after examining the relation between MHCII
+CD16+ and CD14+CD16+ using the following approach.
Human PBMC were examined by an antibody cocktail
composed of anti-CD16, anti-CD14, anti-MHCII antibo-
dies and 7AAD (Figure 4(a)). Cells were first gated by
FSC/SSC (Figure 4(a)-a), followed by dead cell exclusion
with 7AAD (Figure 4(a)-b). MHCII+CD16+ double posi-
tive cells were gated (Figure 4(a)-c), and the percentage of
CD14+ cells in total MHCII+CD16+ cells were analyzed
(Figure 4(a)-d). Based on these data (Figure 4(a)-e), sorting
of MHCII+CD16+ instead of CD14+CD16+ cells provided
twice as many CD16+ cells forOC cultures.
PBMC from five PsA patients and three HC were ster-
ile sorted following the same sorting parameters. Demo-
graphic data on these five patients is summarized in
Table 2. The mean age of these five PsA subjects was 33
years, two had mild and three had severe PsA. They had
six tender and swollen joints on average. Two of the
subjects had dactylitis and one had axial disease. One
subject had received an initial dose of infliximab four
weeks prior to the blood draw but the other subjects
were naïve to anti-TNF agents and DMARDs.
Cells were sorted into three cell populations: MHCII
+CD16-, MHCII+CD16int, and MHCII+CD16+. Sorted
cells were cultured in the presence of RANKL and
M-CSF for eight days, and TRAP-stained. Enumeration
Figure 4 CD16- and CD16+ cells are the major reservoirs of OC precursors in HC and PsA patients, respectively. (a) 30 to 50% of MHCII
+CD16+ cells are CD14+. Human peripheral blood mononuclear cells (PBMC) were isolated from the peripheral blood and stained with an
antibody cocktail composed of MHCII-FITC, CD14-APC, CD16-PE, 7AAD. The gating strategy is sequentially illustrated from a to d. [a] PBMC were
gated by FSC/SSC; [b] live cells were gated by 7AAD; [c] dot plot analysis of MHCII and CD16 expression on live cells; [d] the expression of CD14
on MHCII+CD16+ cells gated from c. Red line is the isotype control and blue line is staining from CD14-APC. The number shown in the
histogram represents the frequency of CD14+ cells per total MHCII+CD16+ cells. [e] The relative percentage of CD14+CD16+ to MHCII+CD16+
cells. Sample shown here is the representative of 3 healthy controls (HC). (b) Human PBMC from HC and psoriatic arthritis (PsA) patients were
isolated, stained with antibodies, and sterile sorted into three populations, MHCII+CD16-, MHCII+CD16int, and MHCII+CD16+. Osteoclastogenesis
was examined by osteoclast (OC) count after eight-day culture in the presence of receptor activator of nuclear factor kappa-B ligand (RANKL)
and macrophage colony-stimulating factor (M-CSF) (MHCII+CD16-: purple, MHCII+CD16int: turquoise, MHCII+CD16+: orange). Subject numbers 1
to 3 are HC and numbers 4 to 8 are PsA patients.
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of OC from different sorted cell populations is summar-
ized by Figure 4(b). Unexpectedly, OCP from HC and
PsA patients arose from different cell subsets. In HC,
OC were derived primarily from CD16- cells (Figure 4
(b), subject numbers 1 to 3), whereas the majority of
OC were derived from CD16+ or CD16int cells in PsA
patients (Figure 4(b), subject numbers 4 to 8). Although
CD16+ cells were the major reservoir of OCP in most
PsA patients (Figure 4(b), subject numbers 5 to 8,
orange bars), it is noteworthy that CD16int cells, instead
of CD16+, were the source of OCP in one of the PsA
subjects (Figure 4(b), subject number 4, turquoise bar).
The results of cell sorting are shown in Table 3. Table 2
summarizes disease activity and patient information at
the time of sample collection. Collectively, our results
indicated that the major reservoirs of OCP in PsA
patients and in HC are CD16+ cells and CD16- cells,
respectively.
Morphologic analysis provides additional support for
the existence of divergent monocyte subsets with OC
differentiation potential in PsA subjects compared with
controls (Figure 5). OC derived from CD16+ monocytes
in PsA subjects (Figure 5(a)) and CD16- cells cultured
from HC (Figure 5(d)) were similar in regard to cell size
and nuclear number. In contrast, OC derived from
CD16- monocytes in PsA (Figure 5(b)) and CD16+
monocytes in HC (Figure 5(c)) displayed similar mor-
phologic features. Furthermore, OCP from PsA subjects
were larger and had more nuclei than those observed in
controls. The relative cell diameter of OC derived from
CD16+ cells in PsA was five times greater than the dia-
meter observed in OC cultured from control CD16-
cells (compare Figure 5(a) with 5(c)). The average
number of nuclei per OC in PsA subjects was 12 ± 1.1
compared with 5 ± 0.2 in HC. The morphological differ-
ences in these cell subsets are summarized in Table 4.
TNFa blocks CD16 expression on a subset of CD14+
monocytes
The level of TNFa is elevated in psoriatic synovium and
synovial fluid [3]. This finding coupled with the marked
reduction of inflammatory signs and symptoms follow-
ing anti-TNFa therapy suggest that TNFa plays a criti-
cal role in PsA pathology. Thus, it is plausible that
elevated TNFa levels may account for the variations in
OC ontogeny between HC and PsA shown in Figure 4
(b). Of note, Skinner and colleagues reported that addi-
tion of TNFa to whole blood cultures of septic patients
induced a marked expansion of CD14+CD16+ cells [25].
To examine this possibility, we analyzed the effect of
TNFa on CD16 expression. Consistent to the data
shown in Figure 1(b), fresh PBMC isolated from PsA
subjects had a higher percentage of CD14+CD16+ cells
than HC (Figure 6(b) vs. 6(a), upper right quadrants,
2.5% vs. 0.32%). In addition, the cell surface expression
of CD16 in PsA was higher (compare the values of the
x-axis on CD14+ cells, upper left and right quadrants,
Figures 6(a) and 6(b)). After three-day culture in plain
media, the percentage of CD14+CD16+ increased in
both HC and PsA samples (0.32 to 5.94 for Figure 6(a)
vs. 6(c), and 2.50 to 3.38 for Figure 6(b) vs. 6(e)), similar
to the result after PBMC were cultured in OC-promot-
ing conditions (Figure 2(b)).
Intriguingly, cells cultured in the presence of TNFa
(Figures 6(d) and 6(f)) were more heterogeneous than
cells cultured in the absence of TNFa (Figures 6(c) and
6(e)). It is likely that the presence of TNFa blocks
CD16 upregulation on some CD14+ cells, resulting in
two distinct CD14+ populations, CD14+CD16+ and
CD14+CD16int (indicated by vertical arrows in Figures 6
(d) and 6(f)). In contrast, the majority of CD14+ cells
upregulated CD16 expression and became CD16+ in the
absence of TNFa (indicated by vertical arrows in Fig-
ures 6(c) and 6(e)). Interestingly, when exposed to
TNFa, cells isolated from PsA patients had higher mean
fluorescence intensities of CD16 expression than HC
cells (compare CD16 expression on X-axis for CD14
+CD16+ cells gated in rectangles, Figure 6(d) vs. 6(f)).
Monocytes with a higher CD16 cell surface expression
have increased bone resorption activity
The finding that the majority of OC in PsA patients
were derived from CD16+ cells (Figure 4(b)); together
with our previous result showing that elevated OCP cor-
relate with joint erosions raised the possibility that the
expression level of cell surface CD16 is associated with
increased bone erosion activity. We examined this
Table 2 Details of disease status for five PsA patients
analyzed in Table 3 and Figure 4(b) at the time of
sample collection
Patient number Age Gender % BSA Joint count
4 38 M 2% 9 T, S jts, 2 DD
5 40 F 4% 9 T, S jts, 2 DD
6 45 M 15% 4 T, S jts severe AD
7 27 M 80% 6 T, S jts
8 26 F 2% 8 T, S jts
AD = axial disease; BSA = body surface area; DD = dactylitic digits; F = female;
jts = joints; M = male; PsA = psoriatic arthritis; S = swollen; T = tender.
Table 3 Enumeration of OC derived from sorted MHCII
+CD16- and MHCII+CD16+ cells in HC and PsA subjects
MHCII+CD16- MHCII+CD16+
OC# (per 105 cells) OC# (per 105 cells)
HC (n = 3) 97.6 ± 10.7 38.0 ± 4.1
PsA (n = 5) 25.8 ± 6.0 313.0 ± 26.1
HC = healthy control; OC = osteoclast; PsA = psoriatic arthritis.
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possibility with the bone wafer assay. MHCII+ cells iso-
lated from three PsA patients were sterile sorted into
CD16-, CD16int, and CD16+ populations and cultured
together with bone wafers in the presence of RANKL
and M-CSF. On day 14, bone wafers were TRAP-stained
for OC quantification, followed by toluidine blue stain-
ing for visualization of erosion pits on the bone surface.
In contrast to MHCII+CD16- cells that generated very
few TRAP+ cells on the bone wafer (data not shown),
both MHCII+CD16int and MHCII+CD16+ cells were
able to develop into mature OC (Figure 7(a)-(b)). Figure
7(c)-(d) shows the corresponding bone erosions on the
same bone wafers. OC derived from the CD16+ subset
generated larger and more numerous pits than those
from CD16int cells (Figure 7(c) vs. 7(d)). Next, we used
the method published by Zhang and colleagues [26] to
quantify bone erosion area. The erosion area of the
CD16+ cells was two-fold larger than that eroded by
CD16int cells (Figure 8(a)). We also noticed that the
depth of erosion pits was also much deeper on the
wafers incubated with CD16+ cells (Figure 7(c) vs. 7(d)).
To confirm this observation, we used micro-CT technol-
ogy to obtain three-dimensional images of these wafers
(Figure 8(b)). In contrast to a moderate bone erosion
observed in CD16int sorted cells (Figure 8(b)-a), a higher
number of pits associated with greater depth were found
Figure 5 OC derived from MHCII+CD16+ and MHCII+CD16- cells of HC and PsA patients have distinct phenotypes. Peripheral blood
mononuclear cells (PBMC) isolated from (a and b) psoriatic arthritis (PsA) and (c and d) healthy controls (HC) and were sterile sorted into (a
and c) MHCII+CD16+ and (b and d) MHCII+CD16- populations. Sorted cells were cultured in the presence of receptor activator of nuclear factor
kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) for eight days, and tartrate-resistant acid phosphatase stained for
osteoclast (OC) quantification. Arrows indicate mature OC. The details of differences in OC generation potential and numbers of nuclei from
these sorted subsets are summarized in Table 4.
Table 4 Summary of OC frequency and nuclear numbers
in PBMC cultures derived from MHCII+CD16+ and MHCII
+CD16- cell subsets in HC and PsA
MHCII+CD16+ MHCII+CD16-
HC 30% of OC 70% of OC
# of nuclei per OC = 3 # of nuclei per OC = 5 ± 0.2
PsA 90% of OC 10% of OC
# of nuclei per OC = 12 ± 1.1 # of nuclei per OC = 3
Percentage of OC- and percentage of OC derived from a particular subject
population (HC vs. PsA).
HC = healthy control; OC = osteoclast; PBMC = peripheral blood mononuclear
cells; PsA = psoriatic arthritis.
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on the wafer incubated with CD16+ sorted cells (Figure
8(b)-b). In conclusion, our results showed that OC
derived from CD16+ monocytes had a higher bone ero-
sion activity than CD16int and CD16- monocytes, which
supports an association between CD16 surface expres-
sion and bone erosion activity.
Discussion
Tissue macrophages are a diverse group of specialized
cells that are pivotal in host defense, wound healing and
immunoregulation [27]. They are thought to arise from
circulating monocytes, which migrate to tissues and
develop specific phenotypes such as Kupffer cells in the
liver, microglial cells in the central nervous system and
OC in bone [27,23]. Circulating monocytes are a hetero-
geneous population characterized by specific cell surface
markers with unique proliferative and physiological
properties that differentiate into specific effector cells in
response to signals present in blood and tissues. Among
these effector cells, OC are of particular interest due to
the central importance of these cells in pathologic bone
resorption in inflammatory arthritis. In previous studies,
Figure 6 CD14+cells from HC and PsA respond differently to TNFa in regards to CD16 cell surface expression. The expression of CD16
on freshly isolated peripheral blood mononuclear cells (PBMC) from healthy control (HC) and psoriatic arthritis (PsA) was shown in (a) and (b),
respectively. After PBMC were cultured in the (c and e) absence or (d and f) presence of TNFa for three days, cell surface expression of CD16
was examined again using the same antibody cocktail composed of anti-CD16 (PE), anti-CD14 (APC), anti-CD3 (Pacific Blue), and anti-CD19 (APC-
Cy7) antibodies with 7AAD. The anti-CD3, anti-CD19 antibodies and 7AAD were included to exclude T cells, B cells, and dead cells, respectively.
Numbers shown in each quadrant (c to f) represent the percentage of cells per total gated live cells. Data shown here are the representative of
two HC and three PsA samples.
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we demonstrated that the frequency of circulating OCP
was greatly increased in a subset of PsA patients parti-
cularly those with joint destruction [3]. Herein, we show
that PsA patients have an elevated percentage of CD14
+CD16+ pro-inflammatory monocytes in the peripheral
blood. Based on the observation of CD16 up-regulation
in cells cultured in OC-promoting (M-CSF and RANKL)
but not DC-promoting conditions (GM-CSF and IL-4),
we examined whether CD16 up-regulation also occurs
in vivo and identified cell subsets that expressed inter-
mediate and high levels of CD16 in PsA. Intriguingly,
we found OC arise from circulating CD16+ monocytes
in PsA, whereas OC were generated from the CD16-
subset in healthy controls. Finally, we showed a positive
correlation between the level of CD16 cell surface
expression and the extent of bone resorption. These stu-
dies indicate that the major reservoir of OCP in PsA is
CD16+ cells, a finding that may catalyze the develop-
ment of susceptibility biomarkers for arthritis in Ps
patients and a treatment response marker in PsA
patients with erosive arthritis.
In general, the CD14+CD16+ monocyte subset is
thought to be more mature than the CD14+CD16- sub-
set [6,7]. CD16+ monocytes release high levels of pro-
inflammatory cytokines and manifest phenotypic and
functional characteristics of macrophages and DC [4,28].
Our results provide evidence that the CD16+ cells can
also differentiate into OC. The existence of CD16int cells
with a lower level of bone resorption suggests that
monocytes exhibit a transitional state in OC differentia-
tion. Additional support for the plasticity of CD16
expression in these cells was the successful conversion
of freshly sterile-sorted CD16- monocytes into CD16+
cells following overnight culture in media without exo-
genous cytokines (data not shown). Collectively, these
data (Figure 2(b)) suggest that monocytes undergo a
transition stage with intermediate expression of CD16
before differentiating into OC, presumably following
exposure to RANKL and M-CSF in the bone marrow,
circulation, and the joint. It is important to note that
the clinical significance of CD14+CD16+ expansion may
depend on the disease state. For example, although
Figure 7 Elevated CD16 surface expression was associated with increased bone erosion activity in PsA monocytes. Sterile sorted MHCII
+CD16+ and MHCII+CD16int cells were co-cultured with bone slices in the presence of receptor activator of nuclear factor kappa-B ligand
(RANKL) and macrophage colony-stimulating factor (M-CSF) for 14 days. (a and b) Osteoclast (OC) were identified by tartrate-resistant acid
phosphatase (TRAP) staining, and (c and d) bone erosion pits were visualized after toluidine blue staining.
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CD14+16+ cells are increased in psoriasis, inflammatory
arthritis and sepsis, the differentiation fate of these cells
is determined by cytokines and chemokines in the local
microenvironment. It is likely that dendritic cells and
inflammatory monocytes predominate in the case of
sepsis, whereas osteoclastogenic cytokines foster OC dif-
ferentiation in inflammatory arthritis.
Consistent with results of Komano and colleagues [24]
and Lari and colleagues [29], our sorting results from
HCs indicate that OC are derived from the CD16-
monocyte subset. We were puzzled by our contradictory
data in PsA subjects where the majority of OC were
derived from CD16+ cells. One plausible explanation is
that elevated levels of inflammatory cytokines and che-
mokines in PsA subjects promote the up-regulation of
CD16 on monocytes. As a result, monocytes isolated
from PsA subjects are more responsive to osteoclasto-
genic factors than those isolated from healthy indivi-
duals. Support for this concept was the finding that
CD16 cell surface expression increased when cells were
cultured with TNF or osteoclastogenic (RANKL + M-
CSF) but not with DC-promoting cytokines (GM-CSF +
IL-4) in vitro. Moreover, intermediate surface expression
of CD16 noted in many Ps and PsA subjects may repre-
sent a transitional state in which monocytes are primed
for osteoclastogenesis in response to environmental
signals.
Although the importance of CD16 in immune regula-
tion was emphasized by its critical role in uncontrolled
systemic infection and sepsis [16,17], the function of
CD16 in osteoclastogenesis remains largely unknown.
Based on current available data, CD16 might be involved
in the regulation of OC development through its ITAM.
CD16 is considered an ITAM-bearing molecule due to
its association with FcRg [16,30]. The regulation of sig-
naling through Fc receptors such as CD16 is extremely
complex. With different affinities to ligand engagement,
ITAM-containing Fc receptors generate either activating
or inhibitory immune response signals [30]. Further-
more, cross-regulation and interaction between ITAM-
associated receptors greatly magnifies the complexity of
this regulation [31]. We propose a similar complex regu-
lation of osteoclastogenesis by CD16 through its ITAM.
To date, except for CD16, many ITAM-bearing surface
receptors involved in OC differentiation have been well
studied [32-34]. Humphrey and colleagues proposed a
model whereby signals delivered by surface ITAM-bear-
ing proteins regulate the expression of many genes
involved in osteoclastogenesis [33]. This model provides
a mechanism to explain the regulation of OC formation
and provides an explanation for the positive correlation
between the CD16 surface expression and bone erosion
activity shown in this study. Current data suggest that
ITAM-bearing proteins might act in concert to program
Figure 8 CD16+ cells have a higher bone resorption activity than CD16int cells. Sterile sorted MHCII+CD16+ and MHCII+CD16int cells were
co-cultured with bone slices in the presence of receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating
factor (M-CSF) for 14 days. (a) Quantification of bone pits eroded by MHCII+CD16int and MHCII+CD16+ cells. (b) Reconstructed three-
dimensional micro-CT images of the bone wafer incubated with MHCII+CD16int [a] and MHCII+CD16+ [b] sorted cells. The data are
representative of three independent sorting experiments.
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cells into a fusion-competent state [35], regulate the
multinucleation process [36], and recruit Syk kinase
[33], similar to the model proposed by Humphrey and
colleagues [33]. Understanding of the interactions
between CD16 and other ITAM-bearing proteins will
likely reveal the contribution of CD16 to osteoclastogen-
esis at the molecular level.
CD16 regulates the production of TNFa by both
direct and indirect mechanisms. Binding of CD16 by
Escherichia coli triggers TNFa secretion [16], and con-
versely, a dramatic decrease in TNFa production is
observed in FcgIII-deficient mice [37]. Recently, Kramer
and colleagues revealed how CD16 activation regulates
TNFa production [38]. Activation of CD16 induces
TNFa through the mitogen-activated protein kinase
pathway but at the same time, CD16 activation can also
limit TNFa production through phosphoinositide 3-
kinase signaling. Of relevance to these findings is the
fact that the proinflammatory CD14+CD16+ monocytes
are major sources of TNFa, a cytokine that potentiates
osteoclastogenesis [13], and IL-6, a cytokine that pro-
motes OC maturation [39]. Therefore, it is likely that
the elevated TNFa in PsA patients is partially responsi-
ble for the increased OCP in these subjects. Currently,
we do not know if the expanded CD14+CD16+ cells are
a major source of TNFa in PsA; however, it appears
that TNFa does not induce CD14+CD16+ expansion
through ‘autocrine’ regulation, because the frequency of
CD14+CD16+ cells decreases in the presence of TNFa
(Figures 6(c) and 6(e) vs. 6(d) and 6(f)). TNFa has a
prominent inhibitory effect on CD16 cell surface expres-
sion for a subset of CD14+ monocytes (indicated by
arrows in Figure 6(e) and 6(f)). This inhibitory effect of
TNFa on CD16 expression was observed for all samples
we processed including controls. Currently, it is unclear
why TNFa blocks CD16 expression in a particular
monocyte subset, resulting in two distinct CD14+ popu-
lations (Figures 6(d) and 6(f), upper left and right
panels). It will be important to determine if the CD14+
cells with high CD16 expression are more likely to dif-
ferentiate into OC compared with CD14+ cells with an
intermediate level of CD16.
In conclusion, OCP derived from PsA patients display
several unique properties compared with OCP that arise
from HC, providing further support to our previous stu-
dies [3]. We showed that OCP arise from different
monocyte populations in PsA subjects and healthy con-
trols. In addition, TNFa upregulation of CD16 cell sur-
face expression on CD14+CD16+ cells was significantly
greater in PsA patients than in HC. We also demon-
strated an expansion of circulating CD14+CD16+ mono-
cytes in PsA subjects and identified cells that express
intermediate levels of CD16. Moreover, surface expres-
sion of CD16 correlated with the extent of bone
resorption in vitro for PsA monocytes. Collectively, our
results suggest a model in which a subset of CD16- cells
undergoes a transition to intermediate CD16 expression
in response to inflammation, and subsequently differ-
entiate into CD16+ cells prior to OC formation. Thus,
CD16 may be a marker for OCP in PsA patients,
although it is highly probable that additional molecules
that specifically characterize this population will be
identified. From a translational perspective, inhibition of
the CD16- to CD16+ transition in circulating monocytes
may have clinical applications for the treatment of meta-
bolic and inflammatory bone disorders.
Conclusions
In conclusion, we found an elevated frequency of circu-
lating CD14+CD16+ cells in PsA subjects compared
with HC. Moreover, the level of CD16 expression corre-
lated with the bone resorption activity. We also demon-
strated that many PsA PBMC cells expressed an
intermediate level of CD16, and the expression of CD16
on fresh human monocytes was enhanced by osteoclas-
togenic cytokines. These data, together with the finding
that OC were derived from the CD16+ population in
PsA patients but not HC, suggest a model in which
OCP undergo a transitional state characterized by a gra-
dual increase in CD16 expression during osteoclastogen-
esis. Collectively, our data indicate that CD16 has the
potential to serve as a marker of OCP in inflammatory
arthritis.
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